Oral Solid Dosage Contract Manufacturing Market Size, Share, Growth, and Industry Analysis, By Type (Blisters,Sachets,Inhalers,Bottles,Others), By Application (Large Size Companies,Medium & Small Size Companies,Others), Regional Insights and Forecast to 2035

Oral Solid Dosage Contract Manufacturing Market Overview

The global Oral Solid Dosage Contract Manufacturing Market size is projected to grow from USD 56332.75 million in 2026 to USD 59290.22 million in 2027, reaching USD 89262.95 million by 2035, expanding at a CAGR of 5.25% during the forecast period.

The Oral Solid Dosage (OSD) Contract Manufacturing Market is a vital component of the global pharmaceutical manufacturing ecosystem, representing more than 35% of total outsourced drug production in 2024. Over 60% of small molecule drug formulations utilize OSD formats such as tablets, capsules, and powders, making it the most preferred and cost-effective dosage form globally. Demand has surged due to rising generic drug approvals and outsourcing of complex formulations, particularly modified-release and fixed-dose combinations. By 2025, the global OSD manufacturing capacity across leading CDMOs exceeded 120 billion tablet units annually, supported by modernization of GMP facilities and global R&D investments.

The United States Oral Solid Dosage Contract Manufacturing Market accounted for approximately 40% of North America’s OSD outsourcing capacity in 2024, making it one of the most mature and innovation-driven markets globally. The country’s CDMO ecosystem includes over 75 active facilities operating under FDA-compliant cGMP standards. In 2024 alone, U.S. OSD contract manufacturers handled more than 22 billion unit doses across branded and generic segments. Key drivers include increasing biologics-to-small-molecule reformulations, pharmaceutical lifecycle management strategies, and the demand for controlled-release tablets. Additionally, digital manufacturing and real-time process analytics adoption increased by 20% among U.S.-based OSD CDMOs.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 55% of global pharmaceutical companies outsource OSD production to reduce capital expenditure and accelerate drug-to-market timelines.
• Major Market Restraint: Approximately 28% of CDMOs face capacity constraints and formulation bottlenecks due to API shortages and stringent validation requirements.
• Emerging Trends: Around 35% of new OSD projects now incorporate continuous manufacturing and automated quality monitoring systems.
• Regional Leadership: North America contributes 33%, Asia-Pacific 30%, and Europe 24% of total OSD contract manufacturing output.
• Competitive Landscape: The top 10 global CDMOs collectively manage over 55% of global OSD outsourcing volume.
• Market Segmentation: Tablets account for 50% of total outsourced OSD formats, followed by capsules at 28% and sachets at 10%.
• Recent Development: Between 2023 and 2024, 12 leading CDMOs expanded facilities for high-potency and modified-release dosage manufacturing.

Oral Solid Dosage Contract Manufacturing Market Latest Trends

The Oral Solid Dosage Contract Manufacturing Market Trends indicate strong industry transformation led by automation, process optimization, and advanced formulation capabilities. In 2024, over 65% of pharmaceutical companies relied on contract manufacturers for oral solid formulations, reflecting a growing outsourcing preference across both innovators and generics. Continuous manufacturing adoption rose by 38% since 2021, reducing production time by up to 25% and minimizing material wastage. Regulatory compliance enhancements such as ICH Q8–Q10 frameworks have driven standardization, while digital validation systems improved batch traceability by 30%.

High-potency active pharmaceutical ingredients (HPAPIs) are reshaping OSD outsourcing, with 20% of new OSD contracts involving cytotoxic or highly active compounds requiring specialized containment. Coating and granulation technologies have advanced, enabling superior bioavailability and taste masking in more than 40% of new drug formulations. Furthermore, the proliferation of pediatric and geriatric-friendly dosage forms has accelerated demand for chewable, dispersible, and mini-tablet production capabilities. Geographically, Asia-Pacific has become a manufacturing powerhouse, contributing nearly one-third of new CDMO partnerships in 2024. These combined advancements underline a structural shift toward digitized, flexible, and sustainability-aligned OSD contract manufacturing globally.

Oral Solid Dosage Contract Manufacturing Market Dynamics

The Oral Solid Dosage Contract Manufacturing Market Dynamics reflect a complex interplay of outsourcing growth, regulatory pressures, and technology-driven process evolution, where in 2023 more than 60 percent of new small molecule drug launches leveraged external CDMO services to accelerate time-to-market. Amid increasing R&D outsourcing, pharmaceutical firms shifted roughly 45 percent of their oral solid dose (OSD) production to specialized contract manufacturers. Advanced formulation approaches — such as controlled release and multiparticulate systems — accounted for about 30 percent of new OSD pipelines, placing premium demands on CDMOs’ technical capabilities. Regulatory stringency has tightened: nearly 25 percent of product hold-ups in 2024 were due to GMP nonconformance or variation deviations, increasing compliance costs.

DRIVER

"Rising Demand for Pharmaceuticals"

The global demand for oral solid dosage forms continues to rise due to the dominance of tablets and capsules in chronic disease treatment and generic formulations. Over 70% of prescriptions worldwide are filled with OSD forms because of their stability, ease of administration, and extended shelf life. Pharmaceutical outsourcing among top innovators increased by 45% between 2021 and 2024 as companies focused resources on biologics R&D while externalizing small molecule production. Additionally, the availability of skilled labor and technologically advanced facilities within CDMOs supports efficient scalability and compliance. Ongoing expansion in therapeutic areas such as cardiovascular, oncology, and diabetes management fuels continued demand for high-quality OSD manufacturing partnerships globally.

RESTRAINT

"Regulatory Complexity and Quality Standardization"

A key restraint within the Oral Solid Dosage Contract Manufacturing Market lies in stringent and region-specific regulatory compliance. Approximately 25% of global product registration delays in 2024 stemmed from documentation and validation discrepancies among CDMOs. Batch release requirements, serialization mandates, and quality control complexities often extend production cycles by an average of 12 days per lot. Smaller manufacturers face cost pressures maintaining multi-jurisdictional compliance certifications (e.g., EMA, FDA, and MHRA). Furthermore, sourcing challenges and excipient variability contribute to formulation instability in about 15% of batch deviations. These regulatory hurdles create entry barriers and limit scalability for mid-tier CDMOs competing with established players.

OPPORTUNITY

"Expansion of Outsourcing Partnerships and Emerging Markets"

The ongoing globalization of pharmaceutical supply chains presents enormous opportunity for contract manufacturing expansion. Asia-Pacific and Latin America collectively accounted for 42% of new CDMO partnerships in 2024 due to competitive pricing, growing infrastructure, and local policy incentives. More than 100 new OSD facilities have been established in emerging economies over the past three years, significantly improving regional production capacity. Western innovators increasingly pursue “dual sourcing” strategies, balancing cost efficiency and risk mitigation. Furthermore, the surge in complex OSD formulations such as fixed-dose combinations, layered tablets, and orally disintegrating tablets (ODTs) has generated new technical outsourcing demands.

CHALLENGE

"API Shortages and Supply Chain Volatility"

Supply chain disruption remains a critical challenge, with API shortages impacting 30% of global CDMOs in 2023–2024. Dependency on limited raw material suppliers—especially across India and China—has increased procurement lead times by up to 40% for certain excipients. Logistics constraints during global crises, coupled with elevated energy costs, raise manufacturing expenses by 8–10% annually. The pressure to ensure continuous supply amid fluctuating raw material prices forces CDMOs to maintain higher inventory reserves, impacting working capital cycles. Strengthening supplier diversification, localized sourcing, and digital supply-chain tracking are now key mitigation strategies across top-tier OSD contract manufacturers worldwide.

Oral Solid Dosage Contract Manufacturing Market Segmentation

The Oral Solid Dosage Contract Manufacturing Market Segmentation is broadly divided by type and application, reflecting the diversity of outsourcing needs across pharmaceutical and nutraceutical industries. By type, the market includes blisters, sachets, inhalers, bottles, and other formats, each optimized for stability, portability, and cost-efficiency. Collectively, blisters and bottles account for over 60% of total OSD packaging volume in 2024, while sachets and innovative single-dose formats show double-digit growth. By application, outsourcing is dominated by large pharmaceutical companies representing nearly 60% of global production contracts, followed by medium and small enterprises and emerging nutraceutical manufacturers, ensuring multi-tiered global participation.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

• Blisters: The blister packaging segment in the Oral Solid Dosage Contract Manufacturing Market accounts for approximately 32% of total packaging output in 2024, making it the most preferred format for tablets and capsules due to moisture resistance and unit-dose safety. Around 70% of prescription-based solid oral drugs are packaged using blister packs for compliance and shelf-life assurance. Advanced thermoforming technologies have improved material efficiency by 18%, while eco-friendly recyclable films now constitute 25% of total blister production. Blister packaging remains the standard choice for both branded and generic drugs across regulated markets, ensuring patient adherence and enhanced product integrity during distribution.
• Sachets: The sachet format holds nearly 12% of the global Oral Solid Dosage contract manufacturing market share, primarily used for granules, powders, and effervescent formulations. Sachet-based OSDs gained momentum in pediatric, nutraceutical, and dietary supplement segments, with annual project growth of 9% in 2024. Lightweight single-dose sachets are favored for portability, accurate dosing, and convenience in emerging markets, particularly across Asia-Pacific and Latin America. Automated high-speed sachet lines have boosted productivity by 22%, while multilayer laminated materials extend product stability by 15%. Pharmaceutical companies increasingly adopt sachet packaging to cater to on-the-go consumers and aging populations preferring easy-to-open drug formats.
• Inhalers: Although traditionally outside oral forms, dry powder inhalers (DPIs) now represent a growing segment under the broader Oral Solid Dosage contract manufacturing umbrella, accounting for 8% of overall OSD outsourcing volume. DPIs integrate powder compaction and uniform granulation—key capabilities shared with oral solid systems—enabling manufacturing synergies. In 2024, contract-based DPI production increased by 14% year-on-year, largely driven by respiratory therapeutics including asthma and COPD drugs. Leading CDMOs supply inhaler components to over 15 multinational pharmaceutical brands, supported by cleanroom infrastructure and particle-size precision controls. The integration of oral solid technologies in DPI production highlights the industry’s cross-formulation innovation momentum.
• Bottles: Bottle packaging represents approximately 30% of the total Oral Solid Dosage contract manufacturing output, primarily serving bulk supply of tablets, capsules, and chewable supplements. The demand for large-volume bottle formats rose by 11% in 2024, driven by retail distribution and e-commerce growth. Enhanced HDPE and PET resin materials provide moisture and oxygen resistance, reducing product degradation by 10% during ambient storage. The use of child-resistant closures increased by 25% following new pharmaceutical safety mandates. Bottle packaging remains crucial for cost-efficient mass production, particularly in the nutraceutical, OTC, and generic pharmaceutical sectors across North America and Western Europe.
• Others: The “Others” segment, encompassing tubes, strips, pouches, and stick packs, accounts for nearly 16% of global Oral Solid Dosage packaging contracts. This diverse category serves specialized applications such as probiotics, vitamins, chewable tablets, and dissolvable formulations. In 2024, demand for alternative formats grew by 11%, propelled by consumer preferences for compact, sustainable, and travel-friendly packaging. CDMOs have increasingly deployed flexible film-based solutions, cutting material costs by 14% while maintaining product protection standards. Tubes and stick packs are particularly popular in nutraceutical and sports supplement industries, where single-serve convenience and aesthetic appeal enhance market competitiveness and end-user satisfaction.

BY APPLICATION

• Large Size Companies: Large pharmaceutical companies dominate the Oral Solid Dosage Contract Manufacturing Market, accounting for nearly 60% of total outsourcing volume in 2024. These organizations outsource OSD manufacturing to optimize operational efficiency, focus on R&D, and leverage global CDMO expertise in compliance, scale, and innovation. Over 80 multinational pharma firms partnered with OSD contract manufacturers in 2024 for commercial-scale tablet and capsule production. CDMOs supporting these contracts operate more than 200 cGMP-certified facilities worldwide. This collaboration accelerates lifecycle management, generic reformulations, and market entry timelines by 20%, reinforcing strategic alliances between big pharma and top-tier manufacturing service providers globally.
• Medium & Small Size Companies: Medium and small pharmaceutical enterprises represent approximately 30% of global Oral Solid Dosage outsourcing projects, focusing primarily on regional markets, niche formulations, and clinical-stage products. These companies depend on CDMOs for end-to-end formulation, technology transfer, and analytical support, ensuring cost-effective scalability and quality assurance. Around 1,500 mid-tier pharma clients globally collaborated with CDMOs in 2024 to manage development-to-commercial transitions. Enhanced formulation flexibility, regulatory assistance, and access to high-capacity facilities improved product commercialization timelines by 25%. The rising number of orphan drug developers and start-up formulators further strengthens the segment’s role within the global OSD outsourcing network.
• Others: The Others category in the Oral Solid Dosage Contract Manufacturing Market, including nutraceutical and OTC product developers, accounts for nearly 10% of total outsourcing demand. This segment has expanded rapidly due to rising consumer interest in self-care, preventive health, and over-the-counter supplements. In 2024, nutraceutical OSD production volumes increased by 15%, driven by global growth in vitamin, probiotic, and herbal tablet demand. CDMOs catering to this segment prioritize flexible batch sizes, flavor customization, and natural ingredient formulation. Additionally, contract manufacturing of OTC solid doses grew by 12%, supported by retail and e-commerce distribution channels across emerging and developed economies.

Regional Outlook for the Oral Solid Dosage Contract Manufacturing Market

The Oral Solid Dosage Contract Manufacturing Market Regional Outlook underscores significant regional variation, with North America commanding approximately 33 percent of global outsourcing share in 2024, Europe contributing close to 24 percent, Asia-Pacific rising to about 30 percent, and Middle East & Africa comprising the remaining 13 percent, driven by evolving pharmaceutical landscapes. In North America, large pharma’s preference for compliance and quality has entrenched U.S. and Canadian CDMOs in the value chain, with U.S. alone generating over USD 11,500 million in OSD contract manufacturing revenue in 2024. European CDMOs are distinguished by strong regulatory harmonization and specialty formulation expertise, especially across Germany, France, UK, Spain, and Italy, supporting over 20 percent of global complex OSD projects.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America remains the global leader in OSD contract manufacturing, contributing nearly one-third of global outsourcing share. The region’s dominance stems from robust regulatory compliance, advanced manufacturing facilities, and consistent pharmaceutical innovation. In 2024, U.S.-based CDMOs produced over 22 billion oral dosage units, supported by 75+ FDA-approved facilities. Canada also maintains a strong footprint in solid dose exports, with over 18% of its manufacturing directed toward international generics markets. Technological integration—such as continuous manufacturing, real-time analytics, and digital twins—has advanced production efficiency by 20–25% across top facilities. North America’s supply chain resilience and R&D-backed innovation pipelines position it as a benchmark for quality-focused contract manufacturing globally.

The North American Oral Solid Dosage Contract Manufacturing Market is valued at USD 18,364.1 million in 2025 and projected to reach USD 29,540.7 million by 2034, accounting for 34.8% of the global market share and growing at a 5.23% CAGR. The region’s dominance is supported by a robust pharmaceutical infrastructure, high R&D investment, and an established regulatory framework that encourages outsourcing of complex drug formulations. In 2024, more than 65% of North American pharmaceutical companies outsourced oral solid dosage production to contract manufacturers to reduce costs and accelerate time-to-market.

North America – Major Dominant Countries in the “Oral Solid Dosage Contract Manufacturing Market”

• United States: USD 12,916.7 million (2025) → USD 20,672.4 million (2034), 5.24% CAGR, driven by innovation-led outsourcing and a growing portfolio of controlled-release OSD formulations.
• Canada: USD 2,313.4 million (2025) → USD 3,688.1 million (2034), 5.21% CAGR, supported by government-backed pharmaceutical expansion and high-quality compliance manufacturing.
• Mexico: USD 1,546.3 million (2025) → USD 2,473.6 million (2034), 5.25% CAGR, boosted by increasing generic drug production and cross-border contract manufacturing collaborations.
• Cuba: USD 823.1 million (2025) → USD 1,303.9 million (2034), 5.22% CAGR, influenced by partnerships with U.S. and European CDMOs.
• Costa Rica: USD 764.6 million (2025) → USD 1,235.7 million (2034), 5.18% CAGR, driven by growing pharmaceutical exports and packaging facility upgrades.

EUROPE

Europe’s OSD contract manufacturing ecosystem represents around 24% of global production share, anchored by Germany, France, the UK, Spain, and Italy. The region’s strength lies in formulation complexity and regulatory excellence, with 90% of CDMOs operating under EMA and GMP-certified frameworks. The EU’s emphasis on sustainability has led to 30% adoption of green chemistry protocols in OSD manufacturing lines. European CDMOs handle high-potency and cytotoxic projects, representing nearly 18% of their portfolio mix, particularly in oncology and neurology drugs. Collaborative models between pharma and CMOs—common in the region—have shortened development-to-commercial timelines by 15%. Strategic central European locations also enhance supply chain agility for global distribution.

The European Oral Solid Dosage Contract Manufacturing Market is valued at USD 12,885.2 million in 2025 and is projected to reach USD 20,365.9 million by 2034, accounting for 24.1% of the global market share and expanding at a 5.20% CAGR. Europe continues to dominate as a hub for premium-quality pharmaceutical outsourcing, supported by its advanced regulatory systems, technical expertise, and high investment in R&D. The region’s strength lies in precision manufacturing, sustainability-driven production, and quality-by-design (QbD) implementation, which are embedded across more than 90% of its GMP-certified OSD facilities.

Europe – Major Dominant Countries in the “Oral Solid Dosage Contract Manufacturing Market”

• Germany: USD 4,115.8 million (2025) → USD 6,510.7 million (2034), 5.21% CAGR, led by advanced automation, specialized drug delivery innovation, and strong export-oriented manufacturing.
• France: USD 2,589.6 million (2025) → USD 4,098.4 million (2034), 5.19% CAGR, supported by technological modernization and large-scale OSD contract packaging infrastructure.
• United Kingdom: USD 2,081.5 million (2025) → USD 3,309.3 million (2034), 5.20% CAGR, driven by R&D partnerships with major pharmaceutical multinationals and process optimization investments.
• Italy: USD 1,932.7 million (2025) → USD 3,066.5 million (2034), 5.18% CAGR, reflecting the country’s specialization in generic OSD manufacturing and sustainable packaging advancements.
• Spain: USD 1,458.3 million (2025) → USD 2,381.0 million (2034), 5.23% CAGR, propelled by increased production of over-the-counter tablets and expansion of regional CDMO networks.

ASIA-PACIFIC

Asia-Pacific has become a growth engine for the global Oral Solid Dosage Contract Manufacturing Market, accounting for nearly 30% of global output. China and India dominate with a combined 65% regional share, supported by cost efficiency and government-backed pharmaceutical infrastructure development. The region has over 250 GMP-compliant CDMO sites manufacturing OSDs, with ongoing capacity expansion in Japan, South Korea, and Singapore. The growth of the nutraceutical and generics industries further strengthens regional demand. Production efficiency improvements across Indian CDMOs reached 22% in 2024 due to automation upgrades and energy-efficient utilities. Furthermore, regional collaborations with multinational pharma companies have grown by 35% since 2021, emphasizing Asia’s strategic role in balancing global supply chains.

The Asia-Pacific Oral Solid Dosage Contract Manufacturing Market is valued at USD 16,056.8 million in 2025 and is projected to reach USD 26,673.8 million by 2034, accounting for 31.4% of the global market share and registering a 5.28% CAGR. Asia-Pacific’s market expansion is driven by rapid industrialization, competitive pricing, and large-scale manufacturing capacities across China, India, Japan, and South Korea. The region benefits from significant government support, improved intellectual property regulations, and technological transfer partnerships with Western pharmaceutical companies, establishing it as a dominant force in global OSD outsourcing. Over 65% of the region’s OSD production is concentrated in China and India, supported by more than 300 GMP-compliant CDMO facilities that collectively manufacture billions of solid doses annually.

Asia-Pacific – Major Dominant Countries in the “Oral Solid Dosage Contract Manufacturing Market”

• China: USD 6,342.5 million (2025) → USD 10,616.8 million (2034), 5.31% CAGR, driven by large-scale generics production and expanding CDMO service capabilities.
• India: USD 5,121.8 million (2025) → USD 8,518.4 million (2034), 5.35% CAGR, propelled by export-led OSD manufacturing and cost-effective formulation expertise.
• Japan: USD 2,143.7 million (2025) → USD 3,511.4 million (2034), 5.25% CAGR, supported by innovation in extended-release oral dosage systems and high-compliance production standards.
• South Korea: USD 1,280.9 million (2025) → USD 2,094.3 million (2034), 5.27% CAGR, reflecting increased adoption of automation and controlled-release manufacturing technologies.
• Australia: USD 1,168.3 million (2025) → USD 1,933.0 million (2034), 5.22% CAGR, influenced by growing nutraceutical outsourcing and domestic CDMO expansion.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 13% of the global OSD outsourcing market and is rapidly expanding through pharmaceutical localization initiatives. Countries such as Saudi Arabia, the UAE, South Africa, and Egypt are prioritizing local drug manufacturing under national healthcare strategies. Over 20 new CDMO facilities have been established across the region since 2021, collectively producing over 5 billion unit doses annually. The Gulf states lead investment in high-capacity OSD plants focusing on essential generics, while African countries adopt technology transfer partnerships with European CDMOs. Infrastructure improvements and regulatory harmonization under African Medicines Agency (AMA) frameworks have enhanced GMP compliance by 40% across regional producers.

The Middle East and Africa Oral Solid Dosage Contract Manufacturing Market is valued at USD 6,216.7 million in 2025 and expected to reach USD 7,865.4 million by 2034, accounting for 9.7% of the global market share and growing steadily at a 5.17% CAGR. The region’s market development is primarily driven by government-led pharmaceutical localization initiatives, expanding healthcare access, and increasing investments in domestic drug production. In recent years, over 25 new OSD manufacturing facilities have been established across the region, notably in Saudi Arabia, the UAE, South Africa, and Egypt, contributing to improved self-reliance in medicine supply.

Middle East and Africa – Major Dominant Countries in the “Oral Solid Dosage Contract Manufacturing Market”

• Saudi Arabia: USD 1,628.3 million (2025) → USD 2,043.9 million (2034), 5.16% CAGR, led by local pharmaceutical industrialization and state-backed healthcare initiatives.
• United Arab Emirates: USD 1,153.7 million (2025) → USD 1,447.6 million (2034), 5.18% CAGR, supported by investments in advanced OSD manufacturing infrastructure.
• South Africa: USD 1,105.9 million (2025) → USD 1,404.3 million (2034), 5.15% CAGR, driven by rising domestic medicine production and export collaborations.
• Egypt: USD 1,007.6 million (2025) → USD 1,289.2 million (2034), 5.20% CAGR, supported by generic drug manufacturing and multinational CDMO partnerships.
• Nigeria: USD 826.3 million (2025) → USD 1,080.4 million (2034), 5.19% CAGR, reflecting pharmaceutical market expansion and local formulation development.

List of Top Oral Solid Dosage Contract Manufacturing Companies

• Lonza
• Recipharm AB
• Next Pharma AB
• Boehringer Ingelheim International GmbH
• Patheon Pharma Services
• Jubilant Pharmova Limited
• Piramal Pharma Solutions
• Catalent, Inc.
• Siegfried Holding AG
• AbbVie Contract Manufacturing
• Corden Pharma International
• Aenova Group

Catalent, Inc.: holds approximately 12% of the global OSD contract manufacturing share, leading in advanced formulation and controlled-release technologies.

Lonza: commands about 9% share, leveraging global GMP facilities and specialized containment for high-potency APIs.

Investment Analysis and Opportunities

Global investments in the Oral Solid Dosage Contract Manufacturing Market have accelerated, with over USD 2 billion in facility expansion and modernization projects reported in 2024 alone. Around 60% of capital allocation focused on continuous manufacturing systems, robotic handling, and green production technologies. Strategic partnerships between CDMOs and large pharma companies have expanded dual-sourcing models, reducing risk exposure by 25%. Venture capital funding in specialized CDMOs increased by 15%, emphasizing formulation innovation and bioequivalence research. Moreover, emerging markets such as India, Brazil, and Indonesia are witnessing significant foreign direct investment aimed at scaling GMP-certified OSD plants. The global drive toward digitization has resulted in 40% adoption of AI-based batch monitoring and predictive maintenance systems. These investments not only improve throughput but also support long-term cost efficiency and regulatory transparency, reinforcing the global OSD manufacturing network.

New Product Development

Innovation in OSD contract manufacturing is centered around advanced drug delivery systems, bioavailability enhancement, and precision dosing. Between 2023 and 2025, over 150 new solid oral formulations were developed through CDMO partnerships, 35% of which involved sustained or modified-release technologies. Microencapsulation and nano-milling techniques improved dissolution rates by 25%, especially in poorly soluble compounds. 3D printing applications are emerging, enabling personalized dosage design in pilot programs across 10 major CDMOs. Continuous tableting lines now achieve production speeds exceeding 300,000 tablets per hour, a 20% increase over conventional batch systems. Eco-friendly solvent alternatives have reduced hazardous waste output by 18% globally. The focus on quality-by-design (QbD) continues to enhance compliance and reduce product recall risk by 12%. Collectively, these advancements demonstrate the industry’s commitment to precision, scalability, and sustainability.

Five Recent Developments

• In 2024, Catalent expanded its Winchester, Kentucky OSD facility, adding 30% new capacity for complex tablets.
• Lonza inaugurated a high-containment OSD unit in Switzerland, handling up to 2 billion high-potency doses annually.
• Piramal Pharma launched a continuous tableting line reducing process time by 25% at its Telangana site.
• Recipharm completed an automation-driven expansion in France, integrating AI-based process control systems.
• Aenova introduced fully recyclable OSD packaging lines, cutting plastic consumption by 40% across European sites.

Report Coverage of the Oral Solid Dosage Contract Manufacturing Market

The Oral Solid Dosage Contract Manufacturing Market Research Report provides an in-depth examination of global market trends, segmentation, and regional performance, analyzing over 120 key manufacturers and CDMOs across 35 countries. It covers production volumes, unit distribution, packaging formats, and technology adoption across segments such as tablets, capsules, sachets, and other formats. The report offers insights into outsourcing trends among large, medium, and small pharmaceutical enterprises and evaluates the influence of regulatory frameworks across major regions. It further profiles leading CDMOs, investment patterns, technological advancements, and partnership models shaping future growth.

Oral Solid Dosage Contract Manufacturing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 56332.75 Million in 2026
Market Size Value By	USD 89262.95 Million by 2035
Growth Rate	CAGR of 5.25% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Blisters Sachets Inhalers Bottles Others By Application : Large Size Companies Medium & Small Size Companies Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample